產品詳情
簡單介紹：
Anti-phospho-PKMYT1 (Thr495)抗體產品質量穩定，實驗效果明顯，貨期快，價格優惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-phospho-PKMYT1 (Thr495)抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-phospho-PKMYT1 (Thr495)
Cat. Number:
Anti-phospho-PKMYT1 (Thr495)抗體KL-5531R
Quantity size:
0.1ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
This gene encodes a member of the serine/threonine protein kinase family. The encoded protein is a membrane-associated kinase that negatively regulates the G2/M transition of the cell cycle by phosphorylating and inactivating Anti-phospho-PKMYT1 (Thr495)抗體cyclin-dependent kinase 1. The activity of the encoded protein is regulated by polo-like kinase 1. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, May 2012]
Also known as:
PKMYT1(phospho T495);cdc2 inhibitory kinase; Membrane associated tyrosine and threonine specific cdc2 inhibitory kinase; Anti-phospho-PKMYT1 (Thr495)抗體Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase; MYT1; Myt1 kinase; PKMYT 1; Pkmyt1; PMYT1_HUMAN; Protein kinase membrane associated tyrosine/threonine 1; Protein kinase Myt1; DKFZp547K1610; FLJ20093.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, .
●
Immunogen: KLH conjugated Anti-phospho-PKMYT1 (Thr495)抗體Synthesised phosphopeptide derived from human PKMYT1 around the phosphorylation site of Thr495.
●
Predicted Molecular Weight: 55kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-phospho-PKMYT1 (Thr495)抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-phospho-PKMYT1 (Thr495)抗體
Optimal working dilutions must be determined by the end user.
